A thrombolytic regimen for high-risk deep venous thrombosis may substantially reduce the risk of postthrombotic syndrome in children.

Abstract:

:Important predictors of adverse outcomes of thrombosis in children, including postthrombotic syndrome (PTS), have recently been identified. Given this knowledge and the encouraging preliminary pediatric experience with systemic thrombolysis, we sought to retrospectively analyze our institutional experience with a thrombolytic regimen versus standard anticoagulation for acute, occlusive deep venous thrombosis (DVT) of the proximal lower extremities in children in whom plasma factor VIII activity and/or D-dimer concentration were elevated at diagnosis, from within a longitudinal pediatric cohort. Nine children who underwent the thrombolytic regimen and 13 who received standard anticoagulation alone were followed from time of diagnosis with serial clinical evaluation and standardized PTS outcome assessments conducted in uniform fashion. The thrombolytic regimen was associated with a markedly decreased odds of PTS at 18 to 24 months compared with standard anticoagulation alone, which persisted after adjustment for significant covariates of age and lag time to therapy (odds ratio [OR] = 0.018, 95% confidence interval [CI] = < 0.001-0.483; P = .02). Major bleeding developed in 1 child, clinically judged as not directly related to thrombolysis for DVT. These findings suggest that the use of a thrombolysis regimen may safely and substantially reduce the risk of PTS in children with occlusive lower-extremity acute DVT, providing the basis for a future clinical trial.

journal_name

Blood

journal_title

Blood

authors

Goldenberg NA,Durham JD,Knapp-Clevenger R,Manco-Johnson MJ

doi

10.1182/blood-2006-12-061234

subject

Has Abstract

pub_date

2007-07-01 00:00:00

pages

45-53

issue

1

eissn

0006-4971

issn

1528-0020

pii

blood-2006-12-061234

journal_volume

110

pub_type

杂志文章

相关文献

BLOOD文献大全
  • Colony-stimulating factor-1-induced oscillations in phosphatidylinositol-3 kinase/AKT are required for caspase activation in monocytes undergoing differentiation into macrophages.

    abstract::The differentiation of human peripheral blood monocytes into resident macrophages is driven by colony-stimulating factor-1 (CSF-1), which upon interaction with CSF-1 receptor (CSF-1R) induces within minutes the phosphorylation of its cytoplasmic tyrosine residues and the activation of multiple signaling complexes. Cas...

    journal_title:Blood

    pub_type: 杂志文章

    doi:10.1182/blood-2009-03-208843

    authors: Jacquel A,Benikhlef N,Paggetti J,Lalaoui N,Guery L,Dufour EK,Ciudad M,Racoeur C,Micheau O,Delva L,Droin N,Solary E

    更新日期:2009-10-22 00:00:00

  • A reliable ex vivo invasion assay of human reticulocytes by Plasmodium vivax.

    abstract::Currently, there are no reliable RBC invasion assays to guide the discovery of vaccines against Plasmodium vivax, the most prevalent malaria parasite in Asia and South America. Here we describe a protocol for an ex vivo P vivax invasion assay that can be easily deployed in laboratories located in endemic countries. Th...

    journal_title:Blood

    pub_type: 杂志文章

    doi:10.1182/blood-2011-04-348748

    authors: Russell B,Suwanarusk R,Borlon C,Costa FT,Chu CS,Rijken MJ,Sriprawat K,Warter L,Koh EG,Malleret B,Colin Y,Bertrand O,Adams JH,D'Alessandro U,Snounou G,Nosten F,Rénia L

    更新日期:2011-09-29 00:00:00

  • Donor T-cell alloreactivity against host thymic epithelium limits T-cell development after bone marrow transplantation.

    abstract::Acute graft-versus-host disease (aGVHD) impairs thymus-dependent T-cell regeneration in recipients of allogeneic bone marrow transplants through yet to be defined mechanisms. Here, we demonstrate in mice that MHC-mismatched donor T cells home into the thymus of unconditioned recipients. There, activated donor T cells ...

    journal_title:Blood

    pub_type: 杂志文章

    doi:10.1182/blood-2006-07-034157

    authors: Hauri-Hohl MM,Keller MP,Gill J,Hafen K,Pachlatko E,Boulay T,Peter A,Holländer GA,Krenger W

    更新日期:2007-05-01 00:00:00

  • Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?

    abstract::A series of alterations in the cellular genome affecting the expression or function of genes controlling cell growth and differentiation is considered to be the main cause of cancer. These mutational events include activation of oncogenes and inactivation of tumor suppressor genes. The elucidation of human cancer at t...

    journal_title:Blood

    pub_type: 杂志文章,评审

    doi:

    authors: Reuter CW,Morgan MA,Bergmann L

    更新日期:2000-09-01 00:00:00

  • CD148 is a membrane protein tyrosine phosphatase present in all hematopoietic lineages and is involved in signal transduction on lymphocytes.

    abstract::Evidence is presented showing that a protein tyrosine phosphatase different from CD45 is present on the membrane of human hematopoietic cells. The molecule recognized by the monoclonal antibody 143-41, which has been classified as CD148 in the VI International Workshop on Leukocyte Differentiation Antigens, was immuno...

    journal_title:Blood

    pub_type: 杂志文章

    doi:

    authors: de la Fuente-García MA,Nicolás JM,Freed JH,Palou E,Thomas AP,Vilella R,Vives J,Gayá A

    更新日期:1998-04-15 00:00:00

  • C-sis and C-abl expression in chronic myelogenous leukemia and other hematologic malignancies.

    abstract::Cellular oncogenes have been localized at the breakpoints of characteristic chromosomal rearrangements occurring in certain hematologic malignancies. This has been reported to result in aberrant expression of the involved oncogenes. Over 90% of chronic myelogenous leukemia (CML) is characterized by a reciprocal transl...

    journal_title:Blood

    pub_type: 杂志文章

    doi:

    authors: Romero P,Blick M,Talpaz M,Murphy E,Hester J,Gutterman J

    更新日期:1986-03-01 00:00:00

  • Interleukin-1beta secretion is impaired by inhibitors of the Atp binding cassette transporter, ABC1.

    abstract::The production of interleukin-1beta (IL-1beta), a powerful mediator of inflammation, is tightly regulated at several levels. However, in some pathologic conditions, a pharmacologic treatment is required to control the toxicity of excessive extracellular IL-1beta. Because of the heavy side effects of most therapies use...

    journal_title:Blood

    pub_type: 杂志文章

    doi:

    authors: Hamon Y,Luciani MF,Becq F,Verrier B,Rubartelli A,Chimini G

    更新日期:1997-10-15 00:00:00

  • The Src kinase Lyn is required for CCR5 signaling in response to MIP-1beta and R5 HIV-1 gp120 in human macrophages.

    abstract::CCR5 is a receptor for several beta chemokines and the entry coreceptor used by macrophage-tropic (R5) strains of HIV-1. In addition to supporting viral entry, CCR5 ligation by the HIV-1 envelope glycoprotein 120 (gp120) can activate intracellular signals in macrophages and trigger inflammatory mediator release. Using...

    journal_title:Blood

    pub_type: 杂志文章

    doi:10.1182/blood-2005-12-012815

    authors: Tomkowicz B,Lee C,Ravyn V,Cheung R,Ptasznik A,Collman RG

    更新日期:2006-08-15 00:00:00

  • Human platelet cytoskeletons: specific content of glycolipids and phospholipids.

    abstract::The lipid composition of platelet cytoskeletons was analyzed. Triton X-100 (0.5%) was used to prepare cytoskeletons from thrombin-treated platelets. The lipid/protein ratio of platelet cytoskeletons was 0.260 and the phospholipid/protein ratio was 0.177, which were comparable to the ratios present in platelets. Howeve...

    journal_title:Blood

    pub_type: 杂志文章

    doi:

    authors: Schick PK,Tuszynski GP,Vander Voort PW

    更新日期:1983-01-01 00:00:00

  • CD40 activation does not protect chronic lymphocytic leukemia B cells from apoptosis induced by cytotoxic T lymphocytes.

    abstract::Cytotoxic T lymphocytes (CTLs) can kill target cells by the granule/exocytosis pathway or the Fas-mediated apoptosis pathway. The sensitivity of chronic lymphocytic leukemia (CLL) B cells to CTL-mediated apoptosis before and after CD40 activation was examined. Resting or CD40-activated CLL cells were found to be equal...

    journal_title:Blood

    pub_type: 杂志文章

    doi:

    authors: Chu P,Wierda WG,Kipps TJ

    更新日期:2000-06-15 00:00:00

  • Anti-IL6-receptor-alpha (tocilizumab) does not inhibit human monocyte-derived dendritic cell maturation or alloreactive T-cell responses.

    abstract::Significant comorbidites and lethality complicate GVHD and its treatment. Targeting the cytokine milieu may improve GVHD control; and IL6 is an attractive candidate, given its role in dendritic cell activation and T-cell differentiation. Tocilizumab is a humanized mAb to IL6-receptor-α (IL6R-α), which is Food and Drug...

    journal_title:Blood

    pub_type: 杂志文章

    doi:10.1182/blood-2011-06-363390

    authors: Betts BC,St Angelo ET,Kennedy M,Young JW

    更新日期:2011-11-10 00:00:00

  • Monoclonal antibodies bound to subunits of the integrin GPIIb-IIIa are internalized and interfere with filopodia formation and platelet aggregation.

    abstract::The monoclonal antibodies Tab and AP3 are directed, respectively, against GPIIb and GPIIIa, the subunits of the platelet fibrinogen receptor. When added together to platelets, these antibodies prevent adenosine diphosphate (ADP)-induced platelet aggregation, despite normal fibrinogen binding (Newman et al, Blood 69:66...

    journal_title:Blood

    pub_type: 杂志文章

    doi:

    authors: Isenberg WM,Bainton DF,Newman PJ

    更新日期:1990-10-15 00:00:00

  • Langerhans cell homeostasis in mice is dependent on mTORC1 but not mTORC2 function.

    abstract::The PI3K/Akt/mTOR pathway has emerged as a critical regulator of dendritic cell (DC) development and function. The kinase mTOR is found in 2 distinct complexes, mTORC1 and mTORC2. In this study, we show that mTORC1 but not mTORC2 is required for epidermal Langerhans cell (LC) homeostasis. Although the initial seeding ...

    journal_title:Blood

    pub_type: 杂志文章

    doi:10.1182/blood-2012-06-439786

    authors: Kellersch B,Brocker T

    更新日期:2013-01-10 00:00:00

  • Identification of the platelet-specific alloantigen, Naka, on platelet membrane glycoprotein IV.

    abstract::We describe the membrane localization of a new platelet-specific alloantigen, designated Naka, that is involved in refractoriness to HLA-matched platelet transfusions. By indirect immunoprecipitation, anti-Naka antibody precipitated a single, radiolabeled platelet membrane protein with a molecular weight (mol wt) of 9...

    journal_title:Blood

    pub_type: 杂志文章

    doi:

    authors: Tomiyama Y,Take H,Ikeda H,Mitani T,Furubayashi T,Mizutani H,Yamamoto N,Tandon NN,Sekiguchi S,Jamieson GA

    更新日期:1990-02-01 00:00:00

  • Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study.

    abstract::The role of glycosylated recombinant human granulocyte colony-stimulating factor (G-CSF) in the induction treatment of older adults with acute myeloid leukemia (AML) is still uncertain. In this trial, a total of 722 patients with newly diagnosed AML, median age 68 years, were randomized into 4 treatment arms: (A) no G...

    journal_title:Blood

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1182/blood-2004-09-3728

    authors: Amadori S,Suciu S,Jehn U,Stasi R,Thomas X,Marie JP,Muus P,Lefrère F,Berneman Z,Fillet G,Denzlinger C,Willemze R,Leoni P,Leone G,Casini M,Ricciuti F,Vignetti M,Beeldens F,Mandelli F,De Witte T,EORTC\/GIMEMA Leukemi

    更新日期:2005-07-01 00:00:00

  • In vivo inhibition by a site-specific catalytic RNA subunit of RNase P designed against the BCR-ABL oncogenic products: a novel approach for cancer treatment.

    abstract::One major obstacle to the effective treatment of cancer is to distinguish between tumor cells and normal cells. The chimeric molecules created by cancer-associated chromosomal abnormalities are ideal therapeutic targets because they are unique to the disease. We describe the use of a novel approach based on the cataly...

    journal_title:Blood

    pub_type: 杂志文章

    doi:

    authors: Cobaleda C,Sánchez-García I

    更新日期:2000-02-01 00:00:00

  • GATA factor mutations in hematologic disease.

    abstract::GATA family proteins play essential roles in development of many cell types, including hematopoietic, cardiac, and endodermal lineages. The first three factors, GATAs 1, 2, and 3, are essential for normal hematopoiesis, and their mutations are responsible for a variety of blood disorders. Acquired and inherited GATA1 ...

    journal_title:Blood

    pub_type: 杂志文章,评审

    doi:10.1182/blood-2016-09-687889

    authors: Crispino JD,Horwitz MS

    更新日期:2017-04-13 00:00:00

  • BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.

    abstract::Clinical resistance to imatinib mesylate is commonly observed in patients with advanced Philadelphia chromosome- positive (Ph(+)) leukemias. Acquired resistance is typically associated with reactivation of BCR-ABL due to kinase domain mutations or gene amplification, indicating that BCR-ABL remains a viable target for...

    journal_title:Blood

    pub_type: 杂志文章

    doi:10.1182/blood-2002-05-1361

    authors: Gorre ME,Ellwood-Yen K,Chiosis G,Rosen N,Sawyers CL

    更新日期:2002-10-15 00:00:00

  • Coactivator function of RIP140 for NFkappaB/RelA-dependent cytokine gene expression.

    abstract::Inflammatory responses represent a hallmark of numerous pathologies including sepsis, bacterial infection, insulin resistance, and malign obesity. Here we describe an unexpected coactivator function for the nuclear receptor interacting protein 140 (RIP140) for nuclear factor kappaB (NFkappaB), a master transcriptional...

    journal_title:Blood

    pub_type: 杂志文章

    doi:10.1182/blood-2007-11-121699

    authors: Zschiedrich I,Hardeland U,Krones-Herzig A,Berriel Diaz M,Vegiopoulos A,Müggenburg J,Sombroek D,Hofmann TG,Zawatzky R,Yu X,Gretz N,Christian M,White R,Parker MG,Herzig S

    更新日期:2008-07-15 00:00:00

  • Morphologic and functional characteristics of bone marrow macrophages from imferon-treated mice.

    abstract::The iron storage macrophage has been isolated from the marrow of Imferon-treated mice and studied in vitro by morphologic, histochemical, and functional tests and isotope labeling techniques. These macrophages on stained preparations are large, many times binucleate cells (up to 150 mu), and show Prussian blue reactiv...

    journal_title:Blood

    pub_type: 杂志文章

    doi:

    authors: Fedorko ME

    更新日期:1975-03-01 00:00:00

  • Sickle cell acute chest syndrome: pathogenesis and rationale for treatment.

    abstract::Acute chest syndrome (ACS) is a leading cause of death in sickle cell disease (SCD). Our previous work showed that hypoxia enhances the ability of sickle erythrocytes to adhere to human microvessel endothelium via interaction between very late activation antigen-4 (VLA4) expressed on sickle erythrocytes and the endoth...

    journal_title:Blood

    pub_type: 杂志文章

    doi:

    authors: Stuart MJ,Setty BN

    更新日期:1999-09-01 00:00:00

  • Distinct apoptotic responses imparted by c-myc and max.

    abstract::The c-myc oncoprotein accelerates programmed cell death (apoptosis) after growth factor deprivation or pharmacological insult in many cell lines. We have shown that max, the obligate c-myc heterodimeric partner protein, also promotes apoptosis after serum withdrawal in NIH3T3 fibroblasts or cytokine deprivation in int...

    journal_title:Blood

    pub_type: 杂志文章

    doi:

    authors: Nesbit CE,Fan S,Zhang H,Prochownik EV

    更新日期:1998-08-01 00:00:00

  • Structural changes in platelet glycoprotein IIb/IIIa by plasmin: determinants and functional consequences.

    abstract::Plasmin exposure modulates platelet aggregation responses, but a direct effect of plasmin on the platelet fibrinogen receptor, glycoprotein IIb/IIIa (GPIIb/IIIa), has never been conclusively shown in a plasma milieu. To examine this issue, we incubated platelets in platelet-rich plasma with plasmin and measured the ef...

    journal_title:Blood

    pub_type: 杂志文章

    doi:

    authors: Pasche B,Ouimet H,Francis S,Loscalzo J

    更新日期:1994-01-15 00:00:00

  • Functional expression of the eotaxin receptor CCR3 in CD30+ cutaneous T-cell lymphoma.

    abstract::Little is known about mechanisms involved in skin-specific homing of cutaneous T-cell lymphoma (CTCL). Chemokine/chemokine receptor interactions have been implicated in the homing of lymphoma cells to various tissue sites. We investigated tissue samples and tumor cell suspensions of patients with CD30(+) CTCL (n = 8) ...

    journal_title:Blood

    pub_type: 杂志文章

    doi:10.1182/blood-2002-02-0475

    authors: Kleinhans M,Tun-Kyi A,Gilliet M,Kadin ME,Dummer R,Burg G,Nestle FO

    更新日期:2003-02-15 00:00:00

  • Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies.

    abstract::Seventy-one patients with hematologic malignancies received bone marrow from a histocompatible sibling (n = 48) or a partially matched relative (n = 23) that had been depleted of CD5+ T cells with either an anti-CD5 mooclonal antibody (MoAb) plus complement (anti-Leu1 + C) or an anti-CD5 MoAb conjugated to ricin A cha...

    journal_title:Blood

    pub_type: 杂志文章

    doi:

    authors: Antin JH,Bierer BE,Smith BR,Ferrara J,Guinan EC,Sieff C,Golan DE,Macklis RM,Tarbell NJ,Lynch E

    更新日期:1991-10-15 00:00:00

  • Fetal erythropoiesis in juvenile chronic myelocytic leukemia.

    abstract::Red cell enzymes, 2,3-diphosphoglycerate (2,3-DPG) and adenosine triphosphate (ATP), were evaluated in a 23-mo-old boy with juvenile chronic myelocytic leukemia (JCML) at the onset of his illness and 6 mo later during the accelerated phase. The activities of the age-dependent red cell enzymes, hexokinase, aldolase, py...

    journal_title:Blood

    pub_type: 杂志文章

    doi:

    authors: Travis SF

    更新日期:1983-09-01 00:00:00

  • Five years of experience with hydroxyurea in children and young adults with sickle cell disease.

    abstract::The short-term beneficial effect of hydroxyurea (HU) in sickle cell disease (SCD) has been proven by randomized studies in children and adults. The Belgian registry of HU-treated SCD patients was created to evaluate its long-term efficacy and toxicity. The median follow-up of the 93 patients registered is 3.5 years; c...

    journal_title:Blood

    pub_type: 杂志文章

    doi:10.1182/blood.v97.11.3628

    authors: Ferster A,Tahriri P,Vermylen C,Sturbois G,Corazza F,Fondu P,Devalck C,Dresse MF,Feremans W,Hunninck K,Toppet M,Philippet P,Van Geet C,Sariban E

    更新日期:2001-06-01 00:00:00

  • Downregulation of interleukin-12 (IL-12) responsiveness in human T cells by transforming growth factor-beta: relationship with IL-12 signaling.

    abstract::Interleukin-12 (IL-12) is a cytokine that plays a central role in the control of cell-mediated immunity. We have previously shown that transforming growth factor-beta1 (TGF-beta) inhibitory effects on human primary allogeneic cytotoxicity and proliferative responses interfere with IL-12 pathway. The present study was ...

    journal_title:Blood

    pub_type: 杂志文章

    doi:

    authors: Pardoux C,Ma X,Gobert S,Pellegrini S,Mayeux P,Gay F,Trinchieri G,Chouaib S

    更新日期:1999-03-01 00:00:00

  • The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia.

    abstract::Chronic myeloid leukemia is effectively treated with imatinib, but reactivation of BCR-ABL frequently occurs through acquisition of kinase domain mutations. The additional approved ABL tyrosine kinase inhibitors (TKIs) nilotinib and dasatinib, along with investigational TKIs such as ponatinib (AP24534) and DCC-2036, s...

    journal_title:Blood

    pub_type: 杂志文章

    doi:10.1182/blood-2011-05-349191

    authors: O'Hare T,Zabriskie MS,Eide CA,Agarwal A,Adrian LT,You H,Corbin AS,Yang F,Press RD,Rivera VM,Toplin J,Wong S,Deininger MW,Druker BJ

    更新日期:2011-11-10 00:00:00

  • Tissue type plasminogen activator regulates myeloid-cell dependent neoangiogenesis during tissue regeneration.

    abstract::Ischemia of the heart, brain, and limbs is a leading cause of morbidity and mortality worldwide. Treatment with tissue type plasminogen activator (tPA) can dissolve blood clots and can ameliorate the clinical outcome in ischemic diseases. But the underlying mechanism by which tPA improves ischemic tissue regeneration ...

    journal_title:Blood

    pub_type: 杂志文章

    doi:10.1182/blood-2009-08-236851

    authors: Ohki M,Ohki Y,Ishihara M,Nishida C,Tashiro Y,Akiyama H,Komiyama H,Lund LR,Nitta A,Yamada K,Zhu Z,Ogawa H,Yagita H,Okumura K,Nakauchi H,Werb Z,Heissig B,Hattori K

    更新日期:2010-05-27 00:00:00